Five Strategic Reasons to Include MRI Biomarkers in Your Next Parkinson’s Study
Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Over 750 industry clinical trials have been initiated for...
At RSNA 2022, our team discussed the latest advances in imaging trials software, including state-of-the-art digital biomarkers algorithms.
Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Over 750 industry clinical trials have been initiated for...
It is difficult to diagnose Parkinson’s disease, and the only way to confirm diagnosis is postmortem. The new imaging AI tools could be the answer.
Sucessfully passed to 2nd phase FICHe grant for novel work on Quantification and Analytics for Parkinson’s disease Mint Labs’ team is happy to...